<DOC>
	<DOCNO>NCT01949701</DOCNO>
	<brief_summary>The investigator previously identify novel HLA-A*0201-restricted epitope peptide , derive cancer-testis antigen , URLC10 target vaccination lung cancer . In clinical study , investigator examine use peptide safety , immunogenicity , antitumor effect vaccine treatment prevent relapse disease HLA-A*0201-positive advance non-small cell lung cancer patient whose disease control standard therapy .</brief_summary>
	<brief_title>Safety Efficacy Study Epitope Peptide To Treat HLA-A*02 Disease Controlled Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description>The purpose study evaluate safety , tolerability , immune response clinical efficacy HLA-A*0201 restrict epitope peptide URLC10 emulsify Montanide ISA 51 disease control advanced non-small cell lung cancer . The investigator previously identify novel HLA-A*0201-restricted epitope peptide , derive cancer-testis antigen , URLC10 target cancer vaccination lung cancer . In phase I/II trial , investigator examine use peptide safety , immunogenicity , antitumor effect vaccine treatment HLA-A*0201-positive advanced non-small cell lung cancer patient whose disease control standard therapy , option additional standard one prevent .future relapse disease .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . NSCLC whose disease control standard therapy , additional standard one prevent .future relapse disease . 2 . ECOG performance status 02 3 . Age 20 85 4 . Clinical efficacy evaluate method 5 . No prior chemotherapy , radiation therapy , hyperthermia immunotherapy within appropriate period 6 . Life expectancy &gt; 3 month 7 . Laboratory value follow 1500/mm3 &lt; WBC &lt; 15000/mm3 Platelet count &gt; 75000/mm3 Asparate transaminase &lt; 3 X cutoff value Alanine transaminase &lt; 3 X cutoff value Total bilirubin &lt; 3 X cutoff value Serum creatinine &lt; 2X cutoff value 8 . HLAA*0201 9 . Able willing give valid write informed consent 1 . Active uncontrolled cardiac disease ( i.e . coronary syndrome , arrhythmia ) 2 . Myocardial infarction within six month entry 3 . Breastfeeding Pregnancy ( woman child bear potential ) 4 . Active uncontrolled infectious disease 5 . Concurrent treatment steroid immunosuppressing agent 6 . Other malignancy require treatment 7 . Noncured traumatic wound 8 . Decision unsuitableness principal investigator physicianincharge</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>